Herantis Pharma Oyj (HEL:HRTIS)

Market Cap	31.32M
Revenue (ttm)	n/a
Net Income (ttm)	-4.94M
Shares Out	24.09M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,599
Average Volume	17,754
Open	1.340
Previous Close	1.300
Day's Range	1.300 - 1.340
52-Week Range	1.180 - 1.750
Beta	0.33
RSI	47.27
Earnings Date	Aug 21, 2025

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 11
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: HRTIS